TORONTO, ON  - TheNewswire - May 13, 2025 - StageZero Life Sciences, Ltd. (TSX:SZLS)(OTCQB:SZLSF) ("StageZero" or the "Company"), and ElevationMD (“ElevationMD”) today announced the introduction of Aristotle and AVRT for the early detection of cancer as well as screening for metabolic markers for identifying and managing the early warning signs of chronic disease for the prevention of cancer.

StageZero is an integrated healthcare company with the first and only mRNA gene expression multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and AVRT, an oncologist-led  metabolic screening and treatment protocol for detecting the early warning signs of cancer and chronic disease, together with ElevationMD today announced they are introducing state of the art early cancer screening to ElevationMD’s patients in British Columbia.

ElevationMD is a physician-led innovative medical clinic.  ElevationMD’s goal is to combine, organize and implement innovative health solutions to deliver exceptional private patient care enabling the detection and prevention of possible future health issues like cancer.

With access to a patient base of 14,000+ this partnership represents a significant opportunity to expand in BC.  ElevationMD belongs to a private network of 22 doctors and is actively growing their doctor roster and patient base.

“ElevationMD is excited to offer both Aristotle and AVRT to its patient base as we continue to build out our innovative health offerings, particularly with the focus on cancer” said Scott Monette, CEO of ElevationMD.

“We are very pleased to partner with ElevationMD and offer Aristotle as part of their comprehensive proactive approach to healthcare.  Specialized tests such as Aristotle are best used inside a clinical offering where the necessary follow up can be easily arranged.  ElevationMD offers exactly this service.” Said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. “The earlier we can find cancer, or identify the risk factors that predispose to cancer, the earlier we can clinically intervene and the greater the opportunity for a successful outcome. For example, ColoRectal cancer found early stage has an approximately 90% 5-year survival rate vs approximately 14% if found late; however, more than half of ColoRectal cancer is detected as late stage cancer. We very much look forward to working with ElevationMD as they bring these innovations to their patients.”

About ElevationMD

Elevation MD is a fully Integrated Longevity Medical Clinic based in Victoria, British Columbia. Tragically, 50% of Canadians will get cancer and 25% will die according to the Government of Canada. Our physician-led longevity clinic helps to fight back by bringing multiple health professionals together with cutting-edge health technology to study your health from various angles allowing us to help prevent many diseases including cancer. Our advocacy and support help patients live in optimal health for as long as possible.

About StageZero Life Sciences, Ltd.

StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and unique telehealth programs that provide clinical interventions to assist patients who currently have cancer (COC Protocol) as well as help patients reduce the risk of developing late-stage chronic disease, with a strong focus on cancer prevention  (AVRT™).

The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Sentinel Principle has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.

The Care Oncology Clinic offers a supervised metabolic treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Developed by scientists and oncologists, the COC Protocol is intended for adjunctive administration alongside standard-of-care cancer therapy.

Aristotle® is processed at the Company's clinical laboratory, StageZero Life Sciences, Inc. in Richmond, Virginia.

Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. There can be no assurance that the FFCTO will be revoked on the timeline contemplated by the Company or that the Company will have the financial resources to meet its obligations with the auditors prior to that deadline. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.  

For further information please contact:
Investor Relations
Rebecca Greco
1-855-420-7140 ext. 1838
rgreco@stagezerols.com